The immune system as anti-tumor sentinel: Molecular requirements for an anti-tumor immune response

Critical Reviews in Oncogenesis

Volumn 10, Issue 3, 1999, Pages 247-260

  Markiewicz, Mary A ^a   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Immune surveillance; T cells; Tumor antigens; Tumor immunity

Indexed keywords

CYTOKINE; GAMMA INTERFERON; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PERFORIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ANIMAL MODEL; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; KNOCKOUT MOUSE; NONHUMAN; REVIEW; TRANSGENIC MOUSE; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032873001     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Amlot, P. L., J. Slaney, and R. Brown: Atopy - a favourable prognostic factor for survival in Hodgkin's Disease. Br. J. Cancer, 48:209-215 (1983).
2. Angiolillo, A. L., C. Sgadari, and G. Tosato: A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann. N.Y. Acad. Sci., 795:158-167 (1996).
3. Baxter, L. T., D. G. Mackensen, H. Zou, and R. K. Jain: Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res., 54:1517-1528 (1994).
4. Bear, H. D., B. M. Susskind, K. A. Close, and S. K. Barret: Phenotype of syngeneic tumor-specific cytotoxic T lymphocytes and requirements for their in vivo generation from tumor-bearing host and immune spleens. Cancer Res., 48:1422-1427 (1988).
5. Birkeland, S. A., H. H. Storm, L. U. Lamm, L. Barlow, L. Blohme, B. Forsberg, B. Eklund, O. Fjeldborg, M. Friedberg, L. Frodin, E. Glattre, S. Halvorsen, N. V. Holm, A. Jakobsen, H. E. Jørgensen , J. Ladefoged, T. Lindholm, G. Lundgren, and E. Pukkala: Cancer risk after renal transplantation in the nordic countries, 1964-1986. Int. J. Cancer, 60:183-189 (1995).
6. Boel, P., C. Wildmann, M.-L. Sense, R. Brasseur, J.-C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity, 2:167-175 (1995).
7. Boon, T.: Genetic analysis of tumor rejection antigens. Cancer Res., 58:177-210 (1992).
8. Brändie, D., R. Brasseur, P. Weynants, T. Boon, and B. van den Eynde: A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med., 183:2501-2508 (1996).
9. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. DePlaen, B. Lethé, P. Coulie, and T. Boon: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178:489-495 (1993).
10. Brichard, V. G., J. Herman, A. Van Pel, C. Wildmann, B. Gaugler, T. Wolfel, T. Boon, and B. Lethé: A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur. J. Immunol., 26:224-230 (1996).
11. Brockmeyer, N. and B. Barthel: Clinical manifestations and therapies of AIDS associated tumors. Eur. J. Med. Res., 3:127-147 (1998).
12. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med., 178:1223-1230 (1993).
13. Burnet, F. M.: The concept of immunological surveillance. Prog. Exp. Tumor Res., 13:1-27 (1970).
14. +cytotoxic T lymphocytes. J. Exp. Med., 181:363-368 (1995).
15. Chaux, P., M. S. Martin, and F. Martin: T-cell costimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor. Int. J. Cancer, 66:244-248 (1996).
16. + T lymphocytes. J. Exp. Med., 189:767-777 (1999).
17. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, F. Liao, M. Farber, S. Pestka, G. Trinchieri, and W. M. Lee: Tumor cell responses to IFN-γ affect tumongenicity and response to IL-12 therapy and antiangiogenesis. Immunity, 9:25-34 (1998).
18. Coulie, P. G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J.-P. Szikora, J.-C. Renauld, and T. Boon: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 180:35-42 (1994).
19. Coulie, P. G., F. Lehmann, B. Lethé, J. Herman, C. Lurquin, M. Andrawiss, and T. Boon: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. U.S.A., 92:7976-7980 (1995).
20. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr.: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science, 264:716-719 (1994).
21. Del Prete, G.: The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int. Rev. Immunol., 16:427-455 (1998).
22. Dighe, A. S., E. Richards, L. J. Old, and R. D. Schreiber: Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity, 1:447-456 (1994).
23. Ehrlich, P.: Ueber den jetzigen Stand der Karzinomforschung. Nederl. Tijdschr. Geneesk., 1:273-290 (1909).
24. Fallarino, F., C. Uyttenhove, T. Boon, and T. F. Gajewski: Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol., 156:1095-1100 (1996).
25. Fallarino, F. and T. F. Gajewski: Differentiation of antitumor CTL in vivo requires host expression of Stat1. Manuscript submitted (1999).
26. Finke, J. H., A. H. Zea, J. Stanley, D. L. Longo, H. Mizoguchi, R. R. Tubbs, R. H. Wiltrout, J. J. O'Shea, S. Kudoh, and E. Klein: Loss of T-cell receptor ζ chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res., 53:5613-5616 (1993).
27. Gajewski, T. F., C. Uyttenhove, F. Fallarino, and T. Boon: Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol., 156:2909-2917 (1996).
28. Gajewski, T. F.: Cancer Immunotherapy. In: Oncologic Therapies, (E. E. Vokes and H. M. Golomb, Eds.) Springer Verlag, Berlin, Heidelberg, 171-204 (1999).
29. Gately, M. K., A. G. Wolitzky, P. M. Quinn, and R. Chizzonite: Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol., 143:127-142 (1992).
30. Gaugler, B., B. van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethé, F. Brasseur, and T. Boon: Human gene MAGE-3 codes for an antigen recognized on a melonoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179:921-930 (1994).
31. Globerson, A. and M. Feldman: Antigenic specificity of benzopyrene-induced sarcomas. J. Natl. Cancer Inst., 32(6):1229-1243 (1964).
32. Greenberg, P. D.: Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol., 49:281-355 (1991).
33. Gross, L.: Intradermal immunization of C3H mice against a sarcoma that originated in the same line. Cancer Res., 3:326-333 (1943).
34. Haas, W., P. Pereira, and S. Tonegawa: γδ cells. Annu. Rev. Immunol., 11:637-685 (1993).
35. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C. Cerottini, and J. Tschopp: Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science, 274:1363-1366 (1996).
36. Halder, T., G. Pawelec, A. F. Kirkin, J. Zeuthen, H. E. Meyer, L. Kun, and H. Kalbacher: Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res., 57:3238-3244 (1997).
37. Henkart, P. A.: Mechanism of lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol., 3:31-58 (1985).
38. Herman, J., P. van der Bruggen, I. Luescher, S. Mandruzzato, P. Romero, J. Thonnard, K. Fleischhauer, T. Boon, and P. G. Coulie: A peptide encoded by human gene MAGE-3 and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Immunogenetics, 43:377-383 (1996).
39. Huang, A. Y., A. T. Bruce, D. M. Pardoll, and H. I. Levitsky: In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity, 4:349-355 (1996a).
40. Huang, A. Y., A. T. Bruce, D. M. Pardoll, and H. I. Levitsky: Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med., 183:769-776 (1996b).
41. Huang, S., W. Hendriks, A. Althage, S. Hemmi, H. Bluethmann, R. Kamijo, J. Vilcek, R. M. Zinkernagel, and M. Auget: Immune response in mice that lack the interferon-γ receptor. Science, 259:1742-1745 (1993).
42. Inge, T. H., S. K. Hoover, B. M. Susskind, S. K. Barrett, and H. D. Bear: Inhibition of tumor-specific cytotoxic T-lymphocytes response by transforming growth factor-β 1. Cancer Res., 52:1386-1392 (1992).
43. Johnsen, A., J. France, M. S. Sy, and C. V. Harding: Downregulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res., 58:3660-3667 (1998).
44. Kang, X., Y. Kawakami, M. El-Gami, R. Wang, K. Sakaguchi, J. R. Yannelli, E. Appella, S. A. Rosenberg, and P. F. Robbins: Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol., 155:1343-1348 (1995).
45. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet, L. J. Old, and R. D. Schreiber: Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A., 95:7556-7561 (1998).
46. Kaplan, M. H., U. Schindler, S. T. Smiley, and M. J. Grusby: Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity, 4:313-319 (1996).
47. Kast, W. M., A. M. Bronkhorst, L. P. de Waal, and C. J. M. Melief: Cooperation between cytotoxic and helper T lymphocytes in protection against lethal sendai virus infection. J. Exp. Med., 164:723-738 (1986).
48. Kast, W. M., R. Offringa, P. J. Peters, A. C. Voordouw, R. H. Meloen, A. J. Van der Eb, and C. J. M. Melief: Eradication of adenovirus E1-induced tumors by E1a-specific cytotoxic T lymphocytes. Cell, 59:603-615 (1989).
49. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. U.S.A., 91:3515-3519 (1994a).
50. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. U.S.A., 91:6458-6462 (1994b).
51. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol., 154:3961-3968 (1995).
52. Klein, G. and T. Boon: Tumor immunology: present perspectives. Curr. Opin. Immunol., 5:687-692 (1993).
53. Kripke, M.: Antigenicity of murine skin tumors induced by ultraviolet light. J. Natl. Cancer Inst., 53:1333-1336 (1974).
54. Lehmann, F., M. Marchand, P. Hainaut, P. Pouillart, X. Sastre, H. Ikeda, T. Boon, and P. G. Coulie: Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melonoma patient are consistent with immune selection. Eur. J. Immunol., 25:340-347 (1995).
55. Ling, W., P. Raymon, R. Uzzo, P. Clark, H. J. Kim, R. Tubbs, A. Novick, R. Bukowski, T. Hamilton, and J. Finke: Impaired activation of NFκB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IκBα. Blood, 92:1334-1341 (1998).
56. Mackey, M. F., J. R. Gunn, P. P. Ting, H. Kikutani, G. Dranoff, R. J. Noelle, and R. J. Barth, Jr.: Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res., 57:2569-2574 (1997).
57. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med., 189:871-876 (1999).
58. Markovic, S. N. and D. M. Murasko: Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma. Cancer Res., 51:1124-1128 (1991).
59. McDuffie, H. H.: Atopy and primary lung cancer: histology and sex distribution. Chest, 99:404-407 (1991).
60. Melief, C. J. M.: Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res., 58:143-175 (1992).
61. Meraz, M. A., J. M. While, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, K. Carver-Moore, R. N. DuBois, R. Clark, M. Auget, and R. D. Schreiber: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell, 84:431-442 (1996).
62. + and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation, 55:1356-1361 (1993).
63. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol., 153:1697-1706 (1994).
64. Ossendorp, F., E. Menged, M. Camps, R. Filius, and C. J. M. Melief: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatability complex class II-negative tumors. J. Exp. Med., 187:693-702 (1998).
65. Pekarek, L. A., B. A. Sarr, A. Y. Toledan, and H. Schreiber: Inhibition of tumor growth by elimination of granulocytes. J. Exp. Med., 181:435-440 (1995).
66. Penninger, J. M., T. Wen, E. Timms, J. Potter, V. A. Wallace, T. Matsuyama, D. Ferrick, B. Sydora, M. Kronenberg, and T. W. Mak: Spontaneous resistance to acute T-cell leukaemias in TCRVγ1.1J γ4Cγ4 transgenic mice. Nature, 375:241-244 (1995).
67. + T cells. J. Exp. Med., 189:757-766 (1999).
68. Robbins, P. F., M. El-Gami, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella, and S. A. Rosenberg: A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med., 183:1185-1192 (1996).
69. Sánchez-Borges, M., A. De Orozco, S. Arellano, V. De Gallego, E. Avila-Millián, and R. Suárez-Chacón: Preventive role of atopy in lung cancer. Clin. Immunol. Immunopath., 41:314-319 (1986).
70. Schmits, R., T. M. Kundig, D. M. Baker, G. Shumaker, J. J. Simard, G. Duncan, A. Wakeham, A. Shahinian, A. van der Heiden, M. F. Bachmann, P. Ohashi, T. W. Mak, and D. D. Hickstein: LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J. Exp. Med., 183:1415-1426 (1996).
71. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. M. Melief: T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 393:480-483 (1998).
72. Schreiber, H.: Tumor immunology. In: Fundamental Immunology, (W. E. Paul, Ed.), Lippincott-Raven, Philadelphia, 1237-1270 (1999).
73. Seliger, B., A. Hohne, H. Knuth, H. Bernhard, B. Ehring, R. Tampe, and C. Huber: Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin. Cancer Res., 2:1427-1433 (1996).
74. Seliger, B., T. Dunn, A. Schwenzer, J. Casper, C. Huber, and H. J. Schmoll: Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP, and MHC class I expression and their upregulation by IFN-γ. Scand. J. Immunol., 46:625-632 (1997).
75. Smith, C., S. Lilly, K. P. Mann, E. Livingston, S. Myers, H. K. Lyerly, and G. D. Miralles: AIDS-related malignancies. Ann. Med., 30:323-344 (1998).
76. Smyth, M. J., J. M. Kelly, A. G. Baxter, H. Kȯrner, and J. D. Sedgwick: An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J. Exp. Med., 188:1611-1619 (1998).
77. Sogn, J. A.: Tumor immunology: the glass is half full. Immunity, 9:757-763 (1998).
78. Sotomayor, E. M., L. Borrello, and H. I. Levitsky: Tolerance and cancer: a critical issue in tumor immunology. Crit. Rev. Oncog., 7:433-456 (1996).
79. Springer, T. A.: Adhesion receptors of the immune system. Nature, 346:425-434 (1990).
80. Springer, T. A.: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell, 76:301-314 (1994).
81. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, L. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky: Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. U.S.A., 95:1178-1183 (1998).
82. Stutman, O.: Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science, 183:534-536 (1974).
83. Stutman, O.: Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J. Natl. Cancer Inst., 62:353-358 (1979).
84. Thomas, L.: Discussion of Cellular and Humoral Aspects of Hypersensitivity States. Hoeber-Harper, New York, 529-532 (1959).
85. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med., 183:1965-1971 (1996).
86. Traversari, C., P. van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176:1453-1457 (1992).
87. Uyttenhove, C., J. Maryanski, and T. Boon: Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med., 157:1040-1052 (1983).
88. van den Broek, B. F., D. Kagi, F. Ossendorp, R. Toes, S. Vamvakas, W. K. Lutz, C. J. M. Melief, R. M. Zinkernagel, and H. Hengartner: Decreased tumor surveillance in perform-deficient mice. J. Exp. Med., 184:1781-1790 (1996).
89. van den Broek, M. F., D. Kagi, D. Zinkernagel, and H. Hengartner: Perform dependence of natural killer cell-mediated tumor control in vivo. Eur. J. Immunol., 25:3514-3516 (1995).
90. van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T Boon: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med., 182:689-698 (1995).
91. van den Eynde, B. J. and P. van der Bruggen: T cell defined tumor antigens. Curr. Opin. Immunol., 9:684-693 (1997).
92. van der Bruggen, P., C. Traversari , P. Chomez, C. Lurquin, E. De Plaen, B. van den Eynde, A. Knuth, and T. Boon: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254:1643-1647 (1991).
93. van der Bruggen, P., J. Bastin, T. Gajewski, P. G. Coulie, P. Boėl, C. De Smet, C. Traversari, A. Townsend, and T. Boon: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol., 24:3038-3043 (1994).
94. van der Bruggen, P., J.-P. Szikora, P. Boël, C. Wildmann, M. Somville, M. Sensi, and T. Boon: Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur. J. Immunol., 24:2134-2140 (1994).
95. Wang, R.-F., M. R. Parkhurst, Y. Kawakami, P. F. Robbins, and S. A. Rosenberg: Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med., 183:1131-1140 (1996).
96. Wolfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K.-H. Meyerzum Buschenfelde, and T. Boon: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol., 24:759-764 (1994).
97. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 269:1281-1284 (1995).
98. Zou, J. P., N. Yamamoto, T. Fujii, H. Takenaka, M. Kobayashi, S. H. Hermann, S. F. Wolf, H. Fujiwara, and T. Hamaoka: Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol., 7:1135-1145 (1995).